CARDIOVASCULAR RISK AND ITS RELATIONSHIP TO METHYLATION IN THE PROMOTERING REGION OF THE BDNF GENE IN ADULTS USERS OF THE PUBLIC HEALTH SYSTEM
Name: PAOLA CERBINO DOBLAS
Publication date: 26/08/2021
Advisor:
Name |
Role |
|---|---|
| IURI DRUMOND LOURO (M/D) | Advisor * |
Examining board:
| Name |
Role |
|---|---|
| ADRIANA MADEIRA ALVARES DA SILVA | Internal Examiner * |
| IURI DRUMOND LOURO (M/D) | Advisor * |
Summary: DOBLAS, P.C. Cardiovascular risk and its relationship to methylation in the promotering region of the BDNF gene in adults users of the Public Health System. 2021. 78p. Dissertation (Master in Biotechnology) - Postgraduation Biotechnological Programme, UFES, Espírito Santo. Brazil.
Cardiovascular diseases are considered the main causes of mortality in the world. For this reason, its important to measure each individual`s cardiovascular risk factors as a prevention method. The Framingham score is a risk stratification method used by different nations. BDNF protein has been associated with different cardiovascular pathologies and risk factors. However, the association between epigenetic regulation and cardiovascular risk is still lacking in the literature. Thus, the main objective was to verify the relationship between cardiovascular risk and methylation rates in the promoter region of exon IV of the BDNF gene in patients using Health Unic System in the city of Alegre, ES. For the methodology, a transveral study was carried out, in which volunteers registered with the HUS, answered a questionnaire on socioeconomic, health, lifestyle and stressors assessments. An anthropometric and biochemical assessment was performed to obtain the necessary data. And DNA was extracted from peripheral blood and quantified by pyrosequencing for methylation analysis. Multivariate statistical analysis was performed by GLzM. As a result, BDNF DNA methylation CpG2 was associated with lower rates of CVR, WHEREas CpGs 4 and 6 were associated with higher rates of CVR. Therefore, there is a relationship between BDNF epigenetic regulation and CVR and further studies are needed to better understand the epigenetic mechanism and its associations with RCV. This and new studies may open doors for the use of BDNF as a possible biomarker for the disease, in order to facilitate diagnosis, act in prevention or even as a therapeutic target for cardiovascular diseases.
Key words: HUS, Exon IV, epigenetics, Framingham score.
